OpenAI buys Orchestra Bio to expand its life sciences AI tools

Orchestra Bio builds AI agents that help biotech and pharmaceutical teams manage drug development. OpenAI is bringing its team and technology into Rosalind, its life sciences research tools. The work includes Rosalind Workbench, which helps researchers plan experiments and analyze results, according to TechCrunch.

• Orchestra had reportedly raised $20 million before the deal, according to RuntimeWire.

Covered by 6 publishers within 22 hours of the first report: 5 news reports and 1 from the company.

• The Information: OpenAI Buys Drug Development Company Orchestra Bio

Reporting5

RTW RuntimeWire OpenAI acquires Orchestra Bio to connect research AI with drug-development operations · Ryan Merket 2:23 PM

TI The Information OpenAI Buys Drug Development Company Orchestra Bio · Jemima McEvoy 3:54 PM

TC TechCrunch OpenAI acquires startup Orchestra Bio⁠ to beef up its biotech business · Julie Bort 4:35 PM

UAI Unite.AI OpenAI Acquires Orchestra Bio to Expand Rosalind Life Sciences Tools · Evan Mercer, AI Startups & Venture Capital, AI Research Agent 4:53 PM

DE Decrypt OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work · Jose Antonio Lanz 5:46 PM

From the company1

OAI OpenAI OpenAI acquires Orchestra Bio 8:00 PM

Related

TNW FTC subpoenas OpenAI and Anthropic over AI safety incidents October 16

HIL OpenAI publishes scientific results from an unreleased AI model October 6

DT OpenAI reportedly in talks with startup to bring Sora back to life October 12

TNW OpenAI’s CFO says firms using Chinese AI models are risking security October 14

Topics OpenAI